Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rVSV Sudan ebolavirus vaccine - Public Health Vaccines

Next Previous
Drug Profile

rVSV Sudan ebolavirus vaccine - Public Health Vaccines

Alternative Names: PHV-03; rVSV-Sudan ebolavirus vaccine - Public Health Vaccines; rVSV-SUDV; rVSV∆G-SUDV GP

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Public Health Vaccine
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ebola virus infections

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (Parenteral)
  • 21 Jun 2023 Preclinical development is ongoing for Ebola-virus-infections (Prevention) in USA (Parenteral) (Public Health Vaccine pipeline, June 2023)
  • 21 Jun 2023 Public Health Vaccine in collaboration with Makerere University plans a phase I/II TOKOMEZA trial for Ebola virus infections (Prevention, In children, In adolescents, In adults) in Uganda (Parenteral) (NCT05909358)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top